BioStock: Cereno Scientific's HDAC inhibitor CS014 advances

Cereno Scientific, which is developing treatments for rare cardiovascular and pulmonary diseases, announces that the first part of the phase I study with the HDAC inhibitor CS014 has been completed without any safety issues. The study evaluates the safety profile of the drug candidate, which is being developed for the treatment of the rare disease idiopathic pulmonary fibrosis (IPF).

Read the articleat biostock.se:

https://www.biostock.se/en/2025/02/cereno-scientifics-hdac-inhibitor-cs014-advances/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/